Filariasis

Lao PDR Reaches Incredible Milestone in Mitigating Neglected Tropical Diseases with Elimination of Lymphatic Filariasis

Retrieved on: 
Wednesday, October 18, 2023

RESEARCH TRIANGLE PARK, N.C., Oct. 18, 2023 /PRNewswire/ -- RTI International, a nonprofit research institute and leading international development organization, joins the Lao People's Democratic Republic (Lao PDR), World Health Organization, and the U.S. Agency for International Development (USAID) in celebrating Lao PDR's achievement of eliminating lymphatic filariasis as a public health problem. 

Key Points: 
  • WHO officially confirmed this week that the people of Lao PDR are no longer at risk of contracting the disease.
  • "It is particularly significant given that Lao PDR achieved the elimination of trachoma as public health problem in 2017, demonstrating the power of national commitment to ending neglected tropical diseases."
  • We are proud to be among the partners that supported the Lao PDR Ministry of Health to achieve this important milestone for its people."
  • The elimination of lymphatic filariasis in Lao PDR was supported by many partners including USAID, RTI, FHI360, WHO, Mac Foundation, and the Asian Development Bank.

Rising Prevalence and Technological Advancements Drive the Lymphedema Treatment Market

Retrieved on: 
Friday, September 22, 2023

The global lymphedema treatment market, valued at $786.53 million in 2021, is projected to grow significantly, reaching $1.74 billion by 2030.

Key Points: 
  • The global lymphedema treatment market, valued at $786.53 million in 2021, is projected to grow significantly, reaching $1.74 billion by 2030.
  • Several factors are contributing to the growth of the lymphedema treatment market:
    Increasing Prevalence: The rising prevalence of lymphedema and breast cancer cases is a significant driver for the market.
  • Technological Advancements: Technological developments in lymphedema treatment methods are expected to accelerate market growth.
  • Despite advancements, there is currently no permanent cure for lymphedema, posing a challenge to market growth.

From fatal allergies to heart attacks and cholera – the devastating health effects of global warming in Africa

Retrieved on: 
Wednesday, September 6, 2023

Wild fires create their own weather systems, generating fire storms with devastating effects.

Key Points: 
  • Wild fires create their own weather systems, generating fire storms with devastating effects.
  • Global warming will increase the number of days of shimmering heat, creating the ideal conditions for fire.
  • Global warming and El Niño combined suggest that the years ahead will result in increasing, devastating impacts.

Heat, air quality and health

    • High temperatures cause heat stroke, heat exhaustion, heart attacks, strokes and other cardiovascular disease.
    • People in informal settlements, and badly maintained and crowded buildings, are especially vulnerable to heat stress.

Less food, lower nutrition

    • In South Africa, drought recurrently affects subsistence agriculture, livestock and commercial crops.
    • The impact of drought on food and nutrition will be felt by the most vulnerable, including infants, small children and pregnant women and those who already live on or below the poverty line.
    • Crop failure and drought, combined with increased food costs associated with disruptions to global food resources, will affect every one of us.

Every drop counts

    • Humans require adequate hydration to survive, and the combination of increasing temperatures and water shortages heightens the risk of organ failure and death.
    • In addition, dependence on poor quality and contaminated water has an impact on household and personal hygiene, and intestinal infections.

Neglected diseases

    • Other viral and bacterial infectious diseases, especially prevalent in Africa, are also likely to increase with global warming.
    • Bundled together as “neglected diseases of poverty”, these include both parasitic and viral vector borne diseases such as Rift Valley fever, malaria, filariasis, schistosomiasis, dengue fever, chikungunya and influenza as well as arboviruses such as different influenza pathogens.

So where does this leave us?

    • When the Intergovernmental Panel on Climate Change was established in 1988, we had a choice to interrupt climate change and slow global warming.
    • This does not mean there is nothing we can do to halt the destruction of planetary life.

Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria and Commitment for Funding to the 3rd Phase of Global Health Innovative Technology Fund Activities

Retrieved on: 
Thursday, May 25, 2023

Eisai has provided a total of 1 billion yen to the first phase (FY2013 - FY2017) and the second phase (FY2018 - FY2022) of the GHIT Fund.

Key Points: 
  • Eisai has provided a total of 1 billion yen to the first phase (FY2013 - FY2017) and the second phase (FY2018 - FY2022) of the GHIT Fund.
  • In order to develop treatments for the numerous people suffering from infectious diseases such as neglected tropical diseases (NTDs) and malaria in developing and emerging countries, there are disease-specific development and marketability issues to overcome.
  • Eisai considers making efforts to resolve the global issue of access to medicines to be its duty.
  • Eisai is also conducting a Phase II clinical trial of antimalarial agent SJ733 in collaboration with the University of Kentucky.

Global Household Insecticides Market Report (2022 to 2027) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 27, 2022

Household insecticides refer to various chemicals that are used for insect control in domestic settings.

Key Points: 
  • Household insecticides refer to various chemicals that are used for insect control in domestic settings.
  • Key Questions Answered in This Report:
    How has the global household insecticides market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global household insecticides market?
  • What is the structure of the global household insecticides market and who are the key players?

Cameroon and the Mectizan Donation Program sign historic agreement to end neglected tropical diseases

Retrieved on: 
Wednesday, July 20, 2022

In the agreement, MDP commits to continuing to make available, free of charge, enough Mectizan for Cameroon's river blindness and LF elimination effort until the World Health Organization declares Cameroon to be free of both diseases.

Key Points: 
  • In the agreement, MDP commits to continuing to make available, free of charge, enough Mectizan for Cameroon's river blindness and LF elimination effort until the World Health Organization declares Cameroon to be free of both diseases.
  • The signing of this agreement is an important step to achieving the elimination targets set by the World Health Organization's Neglected Tropical Diseases Road Map 2021-2030.
  • It will also help to meet the United Nations Sustainable Development Goals (SDG), specifically SDG 3.3to "end the epidemics of HIV, tuberculosis, malaria and neglected tropical diseases" by 2030.
  • The Mectizan Donation Program (MDP) oversees the donation of Mectizan by Merck & Co., Inc., Rahway, New Jersey, USA to eligible countries where river blindness and/or lymphatic filariasis are endemic.

GLIDE Launches Inaugural Awards for Disease Elimination

Retrieved on: 
Wednesday, April 14, 2021

b'The Global Institute for Disease Elimination (GLIDE), a new Abu Dhabi-based global health Institute focused on eliminating infectious diseases of poverty, has launched The Falcon Awards for Disease Elimination, in a drive to discover and implement innovative approaches to disease elimination.\nFounded in 2019 by His Highness Sheikh Mohamed bin Zayed, Crown Prince of Abu Dhabi, and the Bill & Melinda Gates Foundation, GLIDE identifies the latest scientific, cultural, and global health knowledge and puts it into action with partners through programmes to advance disease elimination.\nThe Falcon Awards, which open for submissions online on 4th May 2021, invites Non-Governmental Organisations (NGOs), philanthropic foundations, coalitions or networks of Civil Society Organisations (CSOs), academic or research institutions, Public-Private Partnerships (PPP), and public or private sector institutions in endemic countries to submit proposals that aim to accelerate the elimination of one or more of GLIDE\xe2\x80\x99s four focus diseases: malaria, polio, lymphatic filariasis, and onchocerciasis.\nGLIDE is particularly seeking proposals which address cross-border, cross-disease, cross-programme, or cross-sector approaches to disease elimination.

Key Points: 
  • b'The Global Institute for Disease Elimination (GLIDE), a new Abu Dhabi-based global health Institute focused on eliminating infectious diseases of poverty, has launched The Falcon Awards for Disease Elimination, in a drive to discover and implement innovative approaches to disease elimination.\nFounded in 2019 by His Highness Sheikh Mohamed bin Zayed, Crown Prince of Abu Dhabi, and the Bill & Melinda Gates Foundation, GLIDE identifies the latest scientific, cultural, and global health knowledge and puts it into action with partners through programmes to advance disease elimination.\nThe Falcon Awards, which open for submissions online on 4th May 2021, invites Non-Governmental Organisations (NGOs), philanthropic foundations, coalitions or networks of Civil Society Organisations (CSOs), academic or research institutions, Public-Private Partnerships (PPP), and public or private sector institutions in endemic countries to submit proposals that aim to accelerate the elimination of one or more of GLIDE\xe2\x80\x99s four focus diseases: malaria, polio, lymphatic filariasis, and onchocerciasis.\nGLIDE is particularly seeking proposals which address cross-border, cross-disease, cross-programme, or cross-sector approaches to disease elimination.
  • Submissions should focus on the implementation of innovative ideas and established research which has a high potential to be catalytic, transformational, or genuinely novel in approach, or on operational research with prospects to provide solutions to existing disease elimination challenges.\nSimon Bland, Chief Executive Officer of GLIDE, commented: \xe2\x80\x9cAt GLIDE, we firmly believe in an integrated and collaborative approach to tackling infectious diseases of poverty.
  • The Falcon Awards for Disease Elimination will help advance and amplify these efforts.\xe2\x80\x9d\nFive winners will be announced later this year following a thorough evaluation by a jury panel comprised of esteemed global health experts.
  • Each winner will receive a sum of up to USD200,000 to fund and implement their unique solutions to disease elimination.\nFor more information on The Falcon Awards and how to enter, please visit: https://glideae.org/awards\nThe Falcon Awards - key dates:\nGLIDE is a new global health Institute, rooted in Abu Dhabi, focused on accelerating the elimination of four preventable diseases of poverty: currently malaria, polio, lymphatic filariasis, and river blindness, by 2030 and beyond.

Merck Donates $500,000 to Support River Blindness and Lymphatic Filariasis Elimination Efforts

Retrieved on: 
Thursday, October 22, 2020

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and the MECTIZAN Donation Program (MDP), announced today a $500,000 cash donation to support non-governmental organization (NGO) partners working to eliminate river blindness (onchocerciasis) and lymphatic filariasis (LF).

Key Points: 
  • Merck (NYSE: MRK), known as MSD outside the United States and Canada, and the MECTIZAN Donation Program (MDP), announced today a $500,000 cash donation to support non-governmental organization (NGO) partners working to eliminate river blindness (onchocerciasis) and lymphatic filariasis (LF).
  • The funds are being provided by Merck and will be administered through an application process managed by the MDP, a public-private partnership that oversees elimination efforts of these two diseases.
  • After months of careful assessment, in July, WHO released a decision-making framework for resuming MDA during the ongoing pandemic.
  • The SARS-CoV-2 pandemic is especially challenging for communities that continue to be threatened by river blindness and lymphatic filariasis.

Yemen eliminates lymphatic filariasis (elephantiasis)

Retrieved on: 
Wednesday, September 4, 2019

SANA'A, Yemen, Sept. 4, 2019 /PRNewswire/ -- MSD (trade name of Merck & Co., Inc., Kenilworth, N.J., USA), GSK, and the Mectizan Donation Program congratulate the government, and the people of Yemen for receiving validation by the World Health Organization (WHO) for eliminating lymphatic filariasis as a public health problem.

Key Points: 
  • SANA'A, Yemen, Sept. 4, 2019 /PRNewswire/ -- MSD (trade name of Merck & Co., Inc., Kenilworth, N.J., USA), GSK, and the Mectizan Donation Program congratulate the government, and the people of Yemen for receiving validation by the World Health Organization (WHO) for eliminating lymphatic filariasis as a public health problem.
  • Lymphatic filariasis (LF), commonly known as elephantiasis, is a debilitating disease caused by a parasite transmitted to humans through the bites of mosquitoes.
  • Long-term, chronic infection causes damage to the lymphatic system, and severe and irreversible swelling to the limbs, breasts, and/or genitals.
  • "Lymphatic filariasis is a debilitating, but preventable disease that affects individuals, families and communities.

Elephantiasis (Lymphatic Filariasis) Pipeline Review, H1 2019 Edition - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 8, 2019

The "Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H1 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H1 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Elephantiasis (Lymphatic Filariasis) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Elephantiasis (Lymphatic Filariasis) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Elephantiasis (Lymphatic Filariasis) and features dormant and discontinued projects.
  • The pipeline guide reviews pipeline therapeutics for Elephantiasis (Lymphatic Filariasis) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.